EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aptevo Therapeutics's enterprise value is $46.95 Mil.
Aptevo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-23.79 Mil. Therefore, Aptevo Therapeutics's EV-to-EBITDA for today is -1.97.
The historical rank and industry rank for Aptevo Therapeutics's EV-to-EBITDA or its related term are showing as below:
APVO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1338037.09 Med: -15.15 Max: 0.47
Current: -1.97
During the past 12 years, the highest EV-to-EBITDA of Aptevo Therapeutics was 0.47. The lowest was -1338037.09. And the median was -15.15.
APVO's EV-to-EBITDA is ranked worse than 100% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs APVO: -1.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Aptevo Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Aptevo Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aptevo Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Aptevo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's EV-to-EBITDA falls into.
Aptevo Therapeutics's current Enterprise Value is $46.95 Mil.
Aptevo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aptevo Therapeutics's PE Ratio (TTM) for today is calculated as:
Aptevo Therapeutics's share price for today is $5.508.
Aptevo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-500.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Aptevo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APVO has been successfully added to your 